Table 1.
Clinicopathological characteristics of primary breast cancer patients.
| Diagnostic Age (years) Median (range) |
64 years (44–92) |
|---|---|
| Mammographic Tumor Size n (%) | |
| <2 cm | 15 (51.7) |
| 2 to 5 cm | 13 (44.8) |
| >5 cm | 1 (3.4) |
| Tumor type | |
| CDI | 24 (82.7) |
| CLI | 2 (6.9) |
| Papilar carcinoma | 2 (6.9) |
| Tubular carcinoma | 1 (3.4) |
| Tumor grade n (%) | |
| I | 5 (17.2) |
| II | 16 (55.2) |
| III | 7 (24.13) |
| Unknown | 1 (3.4) |
| Axilar lymph node | |
| Positive | 9 (31.3) |
| Negative | 20 (68.9) |
| Progesterone receptor n (%) | |
| Positive | 12 (41.4) |
| Negative | 17 (58.6) |
| Estrogen receptor n (%) | |
| Positive | 25 (86.20) |
| Negative | 4 (13.79) |
| HER2 status n (%) | |
| Positive | 1 (3.4) |
| Negative | 28 (96.6) |
| IHC subtype n (%) | |
| Luminal A tumor | 14 (48.3) |
| Luminal B tumor | 11 (37.9) |
| HER2-positive tumor | 1 (3.4) |
| Triple negative tumor | 3 (10.3) |
| BIRADS category | |
| 4c | 14 (48.3) |
| 5 | 15 (51.7) |
IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; BIRADS: Breast Imaging-Reporting and Data System.